What is the difference between vildagliptin and sitagliptin

For general information, Learn About Clinical Studies. Written informed consent must be obtained before any assessment is performed. Ability to comply with all study requirements.

Patients with Type 2 diabetes treated with stable, once or twice daily doses minimal dose of 0. Patients receiving metformin must be on a stable dose of metformin at least mg daily or a maximally tolerated dose for at least 12 weeks prior to Visit 1.

Known CV disease based on a documented history of one or more of pre-defined criteria 7. Use of any of the following medications as assessed at Visit Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U.

Federal Government. Read our disclaimer for details. Results First Posted : October 2, Last Update Posted : March 2, Study Description. Drug Information available for: Sitagliptin Sitagliptin phosphate. FDA Resources. Methods: This study was a parallel-arm, randomised, multicentre, double-blind, 24 week study conducted in 87 centres across Brazil and the USA. Patients with type 2 diabetes, either drug naive or treated with any glucose-lowering agents, who had inadequate glycaemic control HbA1c 6.

These doses are recommended in this patient population and considered maximally effective. Participants, investigators and the sponsor were blinded to group assignment. Treatment of T2D patients with kidney disease is more complex. This group is at a higher risk of developing hypoglycemia low blood sugar as a side effect of treatment. Dipeptidyl peptidase-4 DPP-4 inhibitors are drugs used to treat diabetes.

Examples include vildagliptin Xiliarx, Jalra, Galvus and sitagliptin Januvia. DPP-4 inhibitors are approved for treatment of T2D patients with kidney disease. However, few studies have compared different DPP-4 inhibitors. This study compared the effectiveness and safety of vildagliptin and sitagliptin in patients with T2D and severe kidney disease. HbA1c and FPG were tested at the beginning of the study and after 24 weeks.

Side effects related to drug treatment were recorded. There was no significant difference in HbA1c reduction between the 2 groups. HbA1c was reduced by 0. Similarly, there was no significant difference in FPG change between the two groups.

FPG decreased by 0. FPG increased by 0. This study concluded that vildagliptin and sitagliptin are both similarly effective and safe treatments for patients with T2D and kidney disease. Consult your doctor if you are concerned about any of the side effects of vildagliptin or sitagliptin.

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Jalra Shall I go for sitaglipin Zitamet?

What do u mean by halve life? Is daily life spam in the body? Do u mean that the life vildaglipin is less? Hello , I want to know the best one basing on that shelf life?